MA34896B1 - Inhibiteurs du virus de l'hepatite c - Google Patents

Inhibiteurs du virus de l'hepatite c

Info

Publication number
MA34896B1
MA34896B1 MA36169A MA36169A MA34896B1 MA 34896 B1 MA34896 B1 MA 34896B1 MA 36169 A MA36169 A MA 36169A MA 36169 A MA36169 A MA 36169A MA 34896 B1 MA34896 B1 MA 34896B1
Authority
MA
Morocco
Prior art keywords
hepatitis
virus
inhibitors
compounds
methods
Prior art date
Application number
MA36169A
Other languages
English (en)
Inventor
John A Bender
Omar D Lopez
Gan Wang
Makonen Belema
John F Kadow
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45688244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34896(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA34896B1 publication Critical patent/MA34896B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

La présente invention concerne des composés de formule I, des compositions et des méthodes permettant de traiter une infection par le virus de l'hépatite C (VHC). L'invention concerne également des compositions pharmaceutiques contenant de tels composés ainsi que des méthodes d'utilisation de ces composés dans le traitement d'une infection par le VHC.
MA36169A 2011-02-07 2012-02-02 Inhibiteurs du virus de l'hepatite c MA34896B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161440086P 2011-02-07 2011-02-07
US201161467602P 2011-03-25 2011-03-25
PCT/US2012/023595 WO2012109080A1 (fr) 2011-02-07 2012-02-02 Inhibiteurs du virus de l'hépatite c

Publications (1)

Publication Number Publication Date
MA34896B1 true MA34896B1 (fr) 2014-02-01

Family

ID=45688244

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36169A MA34896B1 (fr) 2011-02-07 2012-02-02 Inhibiteurs du virus de l'hepatite c

Country Status (22)

Country Link
US (2) US8552047B2 (fr)
EP (1) EP2673271B1 (fr)
JP (1) JP5815746B2 (fr)
KR (1) KR20140048848A (fr)
CN (1) CN103347878B (fr)
AR (1) AR085327A1 (fr)
AU (1) AU2012214767B2 (fr)
BR (1) BR112013020042A2 (fr)
CA (1) CA2826774A1 (fr)
CL (1) CL2013002241A1 (fr)
CO (1) CO6761335A2 (fr)
EA (1) EA021538B1 (fr)
ES (1) ES2540052T3 (fr)
IL (1) IL227789A0 (fr)
MA (1) MA34896B1 (fr)
MX (1) MX2013008419A (fr)
PE (1) PE20140302A1 (fr)
SG (1) SG192267A1 (fr)
TW (1) TWI542585B (fr)
UY (1) UY33897A (fr)
WO (1) WO2012109080A1 (fr)
ZA (1) ZA201306720B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2012332358B2 (en) 2011-11-03 2017-07-13 Theravance Biopharma R&D Ip, Llc Rod -like hepatitis C virus inhibitors containing the fragement {2- [4- (bi phenyl - 4 - yl) - 1H - imidazo - 2 - yl] pyrrolidine - 1 - carbonlymethyl} amine
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP6069491B2 (ja) 2012-04-25 2017-02-01 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ｃ型肝炎ウイルス阻害剤としてのピペラジン−ピペリジン化合物
CN104884455B (zh) * 2012-10-24 2017-09-12 百时美施贵宝公司 丙型肝炎病毒抑制剂
US9233974B2 (en) * 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2015009744A1 (fr) 2013-07-17 2015-01-22 Bristol-Myers Squibb Company Associations comprenant des dérivés de biphényle destinées à être utilisées pour le traitement du virus de l'hépatite c
US9762562B2 (en) * 2013-09-13 2017-09-12 Facebook, Inc. Techniques for multi-standard peer-to-peer connection
WO2015088817A1 (fr) * 2013-12-11 2015-06-18 Bristol-Myers Squibb Company Dérivés de 4,4'-biphényldiyl bis-(1h-imidazolyle) comme inhibiteurs du vhc
CN104860931A (zh) * 2014-02-21 2015-08-26 常州寅盛药业有限公司 丙肝病毒抑制剂及其制药用途
US20150361087A1 (en) * 2014-06-12 2015-12-17 Gilead Sciences, Inc. Antiviral compounds
US10518123B2 (en) 2014-06-13 2019-12-31 Nautilus, Inc. Adjustable dumbbell system
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN109456375B (zh) * 2018-12-11 2019-10-22 枣庄学院 一种抑制丙肝病毒的含单糖基杂环类化合物及制备方法
US11857827B2 (en) 2021-11-19 2024-01-02 Nautilus, Inc. Plate-sensing base for a connected adjustable free weight system
CN117105928B (zh) * 2023-08-22 2024-03-26 上海蓝木化工有限公司 一种蛋白酶抑制剂及其制备方法

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0679153A4 (fr) 1993-01-14 1996-05-15 Magainin Pharma Acides amines et peptides a terminaisons modifiees.
US5654451B1 (en) 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
EP1532118A2 (fr) 2002-07-05 2005-05-25 Axxima Pharmaceuticals Aktiengesellschaft Composes d'imidazole pour le traitement des infections par le virus de l'hepatite c
WO2004014852A2 (fr) 2002-08-12 2004-02-19 Bristol-Myers Squibb Company Iminothiazolidinones s'utilisant comme inhibiteurs de replication du vhc
DE102004036971B4 (de) 2004-07-30 2009-07-30 Advanced Micro Devices, Inc., Sunnyvale Technik zur Bewertung lokaler elektrischer Eigenschaften in Halbleiterbauelementen
WO2006022442A1 (fr) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. Nouveaux derives d’amides heterocycliques ayant une activite d’inhibition de la dihydroorotate deshydrogenase
GB2438802A (en) 2005-02-28 2007-12-05 Univ Rockefeller Structure of the hepatitis C virus NS5A protein
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
JP2009508835A (ja) 2005-09-16 2009-03-05 アロー セラピューティクス リミテッド ビフェニル誘導体及びｃ型肝炎の治療におけるその使用
WO2007058384A1 (fr) 2005-11-17 2007-05-24 Osaka University Procede d'inhibition de la replication du virus de l'hepatite c, inhibiteur de replication du virus et procede de selection de cet inhibiteur
RU2441869C2 (ru) 2005-12-21 2012-02-10 Эбботт Лэборетриз Противовирусные соединения
WO2007081517A2 (fr) 2005-12-21 2007-07-19 Abbott Laboratories Composes anti-viraux
SG133452A1 (en) 2005-12-30 2007-07-30 Novartis Ag Peptide deformylase inhibitors for treatment of mycobacterial and other parasitic diseases
BRPI0712806A2 (pt) 2006-05-30 2012-10-23 Arrow Therapeutics Ltd uso de um composto, derivado de bifenila ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, produto, e, método para melhorar uma infecção por hepatite c em um paciente
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100158862A1 (en) 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN101558059B (zh) * 2006-08-11 2014-12-03 百时美施贵宝公司 丙型肝炎病毒抑制剂
US7745636B2 (en) 2006-08-11 2010-06-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW200831084A (en) 2006-11-21 2008-08-01 Genelabs Tech Inc Anti-viral compounds
WO2008133753A2 (fr) 2006-12-20 2008-11-06 Abbott Laboratories Composés antiviraux
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
US8093243B2 (en) 2008-02-12 2012-01-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7906655B2 (en) 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8383094B2 (en) 2008-10-01 2013-02-26 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8729077B2 (en) 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
PT2373172E (pt) 2008-12-03 2013-10-21 Presidio Pharmaceuticals Inc Inibidores de ns5a de hcv
SG171891A1 (en) 2008-12-03 2011-07-28 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
CN102264737A (zh) 2008-12-23 2011-11-30 雅培制药有限公司 抗病毒化合物
WO2010091413A1 (fr) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Dérivés du dibenzimidazole liés
WO2010096462A1 (fr) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Dérivés du diimidazole lié
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
WO2010094977A1 (fr) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Nouveaux composés de biphényle utiles pour le traitement de l'hépatite c
CA2753313A1 (fr) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibiteurs du ns5a du vhc
BRPI1007836A2 (pt) 2009-02-27 2015-09-01 Enanta Phamaceuticals Inc Inibidores do vírus c da hepatite
UA108351C2 (uk) 2009-03-27 2015-04-27 Інгібітори реплікації вірусу гепатиту c
EP2410841A4 (fr) 2009-03-27 2012-10-24 Presidio Pharmaceuticals Inc Inhibiteurs bicycliques du vhc substitués
WO2010111534A1 (fr) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Inhibiteurs à noyaux fusionnés de l'hépatite c
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US20110237636A1 (en) 2009-03-30 2011-09-29 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20120115918A1 (en) 2009-04-15 2012-05-10 Abbott Laboratories Anti-Viral Compounds
CN102459165B (zh) 2009-04-15 2015-09-02 Abbvie公司 抗病毒化合物
JP2012524761A (ja) 2009-04-24 2012-10-18 テイボテク・フアーマシユーチカルズ ジアリールエーテル類
WO2010132538A1 (fr) 2009-05-12 2010-11-18 Schering Corporation Composés aryles tricycliques condensés utiles pour le traitement de maladies virales
TW202042807A (zh) 2009-05-13 2020-12-01 美商基利法瑪席特有限責任公司 抗病毒化合物
EP2435421A1 (fr) 2009-05-29 2012-04-04 Schering Corporation Composés antiviraux constitués de trois fractions d'aryle alignées pour traiter des maladies telles que l'hépatite c
WO2010138791A1 (fr) 2009-05-29 2010-12-02 Schering Corporation Composés antiviraux de trois fractions d'aryle liées pour traiter des maladies telles que l'hépatite c
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
CN103819459B (zh) 2009-06-11 2017-05-17 艾伯维巴哈马有限公司 抗病毒化合物
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2010148006A1 (fr) 2009-06-16 2010-12-23 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
WO2011004276A1 (fr) 2009-07-06 2011-01-13 Pfizer Limited Inhibiteurs du virus de l’hépatite c
CA2767887A1 (fr) 2009-07-16 2011-01-20 Vertex Pharmaceuticals Incorporated Analogues du benzimidazole pour le traitement ou la prevention des infections a flavivirus
CN102471324B (zh) 2009-08-07 2014-12-17 泰博特克药品公司 作为丙型肝炎病毒抑制剂的双苯并咪唑衍生物
RU2538507C2 (ru) 2009-08-07 2015-01-10 Тиботек Фармасьютикалз Фенилэтинильные производные в качестве ингибиторов вируса гепатита с
US20120172368A1 (en) 2009-09-03 2012-07-05 Koen Vandyck Bis-Benzimidazole Derivatives
EP3006441A1 (fr) 2009-09-04 2016-04-13 Janssen Pharmaceuticals, Inc. Inhibiteurs de ns5a
EP2475254A4 (fr) 2009-09-11 2013-05-22 Enanta Pharm Inc Inhibiteurs du virus de l'hépatite c
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8415374B2 (en) 2009-10-12 2013-04-09 Bristol-Myers Squibb Company Combinations of hepatitis C virus inhibitors
WO2011050146A1 (fr) 2009-10-23 2011-04-28 Glaxosmithkline Llc Composés chimiques
UA108211C2 (uk) 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) * 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) * 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CA2782024A1 (fr) 2009-11-25 2011-06-03 Schering Corporation Composes tricycliques fusionnes et leurs derives utiles pour le traitement de maladies virales
WO2011068941A2 (fr) 2009-12-04 2011-06-09 National Health Research Institutes Dérivés de proline
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2010330862B2 (en) 2009-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
CN102791687B (zh) 2009-12-18 2015-02-11 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
JP2013515068A (ja) 2009-12-22 2013-05-02 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス性疾患の治療のための縮合三環式化合物およびその使用方法
JP2013515746A (ja) 2009-12-24 2013-05-09 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド フラビウイルス感染症の治療又は予防のための類似体
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091446A1 (fr) 2010-01-22 2011-07-28 Glaxosmithkline Llc Composés chimiques
KR20120107529A (ko) 2010-01-25 2012-10-02 이난타 파마슈티칼스, 인코포레이티드 Ｃ형 간염 바이러스 억제제
JP2013518062A (ja) 2010-01-28 2013-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎阻害化合物
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
BR112012022311A2 (pt) 2010-03-04 2016-08-23 Enanta Pharm Inc agentes farmacêuticos de combinação como inibidores da replicação de hcv.
EA201290882A1 (ru) 2010-03-09 2013-04-30 Мерк Шарп Энд Домэ Корп. Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний
AU2011232348A1 (en) 2010-03-24 2012-10-11 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of Flavivirus infections
EP2550267A1 (fr) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues pour traiter ou prévenir les infections à flavivirus
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
WO2011127350A1 (fr) 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US8877707B2 (en) 2010-05-24 2014-11-04 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
EP2575475A4 (fr) 2010-05-28 2013-11-27 Presidio Pharmaceuticals Inc Inhibiteurs de ns5a de vhc
EP2575819A4 (fr) * 2010-06-04 2013-11-27 Enanta Pharm Inc Inhibiteurs du virus de l'hépatite c
TW201201801A (en) 2010-06-09 2012-01-16 Presidio Pharmaceuticals Inc Inhibitors of HCV NS5A protein
WO2011154871A1 (fr) 2010-06-10 2011-12-15 Pfizer Limited Inhibiteurs du virus de l'hépatite c
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
WO2012003642A1 (fr) 2010-07-09 2012-01-12 Merck Sharp & Dohme Corp. Composés tricycliques condensés et leur utilisation pour le traitement de maladies virales
CN103180310B (zh) 2010-07-26 2015-11-25 爱尔兰詹森科学公司 作为hcv抑制剂的杂二环衍生物
CA2805440A1 (fr) 2010-07-26 2012-02-09 Merck Sharp & Dohme Corp. Composes de biphenylene substitue et procedes d'utilisation desdits composes pour le traitement de maladies virales
CN103153986B (zh) 2010-08-04 2014-11-05 百时美施贵宝公司 丙型肝炎病毒抑制剂
US20120196794A1 (en) 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
WO2012021704A1 (fr) 2010-08-12 2012-02-16 Enanta Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
US20120195857A1 (en) * 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2012020036A1 (fr) 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Inhibiteurs du virus de l'hépatite c
EP2963034A1 (fr) 2010-08-26 2016-01-06 RFS Pharma, LLC. Inhibiteurs puissants et sélectifs du virus de l'hépatite c
US8822520B2 (en) 2010-09-22 2014-09-02 Presidio Pharmaceuticals, Inc. Substituted bicyclic HCV inhibitors
WO2012050848A1 (fr) 2010-09-29 2012-04-19 Schering Corporation Dérivés tétracycliques condensés et procédés d'utilisation de ceux-ci dans le traitement de maladies virales
WO2012040923A1 (fr) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Dérivés d'indoles tétracycliques et leurs méthodes d'utilisation pour le traitement de maladies virales
MX2013003634A (es) 2010-09-29 2013-05-20 Merck Sharp & Dohme Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
WO2012050918A2 (fr) 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Inhibiteurs de l'hépatite c tricyliques à cycles fusionnés
WO2012041227A1 (fr) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques pour le traitement d'une infection par le virus de l'hépatite c
WO2012040924A1 (fr) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Composés hétérocycliques tétracycliques condensés et leurs méthodes d'utilisation pour le traitement de maladies virales
CA2811662A1 (fr) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Derives d'indoles tetracycliques pour le traitement d'une infection par le virus de l'hepatite c
WO2012048421A1 (fr) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Composés inhibiteurs de l'hépatite c
CA2814534A1 (fr) 2010-11-04 2012-05-10 Theravance, Inc. Nouveaux inhibiteurs du virus de l'hepatite c
CA2817840A1 (fr) 2010-11-17 2012-05-24 Gilead Sciences, Inc. Composes antiviraux
RU2452735C1 (ru) 2010-11-30 2012-06-10 Александр Васильевич Иващенко Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
WO2012083043A1 (fr) 2010-12-15 2012-06-21 Abbott Laboratories Composés anti-viraux
US20150232455A1 (en) 2010-12-15 2015-08-20 Allan C. Krueger Anti-viral compounds
WO2012083061A2 (fr) 2010-12-15 2012-06-21 Abbott Laboratories Composés anti-viraux
EP2651920A4 (fr) 2010-12-15 2014-12-17 Abbvie Inc Composés anti-viraux
EP2651926A4 (fr) 2010-12-15 2014-07-09 Abbvie Inc Composés anti-viraux
WO2012083058A2 (fr) 2010-12-15 2012-06-21 Abbott Laboratories Composés anti-viraux
CA2819894A1 (fr) 2010-12-16 2012-06-21 Abbvie Inc. Composes antiviraux
WO2012087976A2 (fr) 2010-12-21 2012-06-28 Intermune, Inc. Nouveaux inhibiteurs de la réplication du virus de l'hépatite c
WO2012123298A1 (fr) 2011-03-11 2012-09-20 F. Hoffmann-La Roche Ag Composés antiviraux
WO2012122716A1 (fr) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Dérivés tétracycliques de xanthène et leurs procédés d'utilisation pour le traitement de maladies virales
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20150105548A1 (en) 2011-05-26 2015-04-16 Abbvie Inc Anti-viral compounds
WO2012162578A2 (fr) 2011-05-26 2012-11-29 Abbvie Inc. Composés antiviraux
MX349079B (es) 2011-05-27 2017-07-07 Achillion Pharmaceuticals Inc Alifanos, ciclofanos, heterafanos, heterofanos, hetero-heterafanos y metalocenos sustituidos utiles para tratar infecciones por el vhc.
US20120328565A1 (en) 2011-06-24 2012-12-27 Brinkman John A Antiviral compounds
WO2013007106A1 (fr) 2011-07-09 2013-01-17 广东东阳光药业有限公司 Composés spiro en tant qu'inhibiteurs du virus de l'hépatite c
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
CA2826774A1 (fr) 2012-08-16
US8552047B2 (en) 2013-10-08
US9340520B2 (en) 2016-05-17
CN103347878B (zh) 2015-05-06
KR20140048848A (ko) 2014-04-24
EP2673271B1 (fr) 2015-05-06
CO6761335A2 (es) 2013-09-30
TWI542585B (zh) 2016-07-21
EP2673271A1 (fr) 2013-12-18
ZA201306720B (en) 2015-05-27
JP2014504643A (ja) 2014-02-24
CL2013002241A1 (es) 2013-12-13
MX2013008419A (es) 2013-09-13
PE20140302A1 (es) 2014-03-24
SG192267A1 (en) 2013-09-30
CN103347878A (zh) 2013-10-09
EA201391152A1 (ru) 2013-12-30
EA021538B1 (ru) 2015-07-30
IL227789A0 (en) 2013-09-30
TW201307333A (zh) 2013-02-16
AU2012214767B2 (en) 2016-06-02
AU2012214767A1 (en) 2013-09-26
AR085327A1 (es) 2013-09-25
US20130028859A1 (en) 2013-01-31
NZ615067A (en) 2014-12-24
US20140012020A1 (en) 2014-01-09
BR112013020042A2 (pt) 2016-10-25
JP5815746B2 (ja) 2015-11-17
WO2012109080A1 (fr) 2012-08-16
ES2540052T3 (es) 2015-07-08
UY33897A (es) 2012-08-31

Similar Documents

Publication Publication Date Title
MA34896B1 (fr) Inhibiteurs du virus de l'hepatite c
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c
MA33731B1 (fr) Inhibiteurs du virus de l'hépatite c
MA35132B1 (fr) 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MA37712A2 (fr) Inhibiteurs macrocycliques de virus flaviviridae
MA37942A2 (fr) Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
MA29240B1 (fr) Derives d'indole pour le traitement d'infections virales
EA201001274A1 (ru) Имидазолилбифенильные имидазолы в качестве ингибиторов вируса гепатита с
EA201001273A1 (ru) Ингибиторы вируса гепатита с
MA35109B1 (fr) Derives de nucleoside 2-substitues et procedes d'utilisation de ceux-ci pour le traitement de maladies virales
MA34147B1 (fr) Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
UA118010C2 (uk) Інгібітори реплікації вірусів грипу
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
EA201390190A1 (ru) Ингибиторы вируса гепатита с
EA201270656A1 (ru) Ингибиторы вируса гепатита с
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
ATE551337T1 (de) Inhibitoren des hepatitis-c-virus
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
EA201590358A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA201171208A1 (ru) Ингибиторы вируса гепатита с
EA201201665A1 (ru) Новые соединения
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MX2013006846A (es) Inhibidores de la replicacion de los virus de la influenza.